A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
260actual
Sites
60
Countries
Austria, Canada, China +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-24 | actual | When the study began enrolling |
| Primary completion | 2025-07-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-25 | actual | The whole study's end, after follow-up |
| First posted | 2023-02-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pulmonary Hypertension (World Health Organization Group 2)
- Heart Failure
Interventions
- Drug: AZD3427
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline in Pulmonary Vascular Resistance (PVR)
measured Baseline to Week 25
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed